Rigel Pharmaceuticals, Inc. (RIGL) financial statements (2020 and earlier)

Company profile

Business Address 1180 VETERANS BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9812911675126143212
Cash and cash equivalents23763818431521
Short-term investments7652775783128191
Receivables104  066
Inventory, net of allowances, customer advances and progress billings11    
Inventory11     
Advances on inventory purchases3      
Other undisclosed current assets6321322
Total current assets:11913711776129151220
Noncurrent Assets
Property, plant and equipment2111234
Other noncurrent assets1111112
Other undisclosed noncurrent assets26      
Total noncurrent assets:29222346
TOTAL ASSETS:14813911978132154226
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities202013111057
Accounts payable4636324
Accrued liabilities743111 
Employee-related liabilities91074633
Deferred revenue and credits 31621
Contract with customer, liability25 
Other undisclosed current liabilities13859872
Total current liabilities:58281823341410
Noncurrent Liabilities
Long-term debt and lease obligation10      
Long-term debt, excluding current maturities10      
Liabilities, other than long-term debt7000358
Deferred revenue and credits000357
Contract with customer, liability1 
Other liabilities5 00000
Total noncurrent liabilities:16000358
Total liabilities:75281823371918
Stockholders' equity
Stockholders' equity attributable to parent541101015591128208
Common stock0000000
Additional paid in capital1,3301,3191,2391,1161,0831,0681,057
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0)0
Accumulated deficit(1,276)(1,209)(1,139)(1,061)(992)(940)(849)
Total stockholders' equity:541101015591128208
Other undisclosed liabilities and equity191 036 
TOTAL LIABILITIES AND EQUITY:14813911978132154226

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues59454202987
Revenue, net4202987
Cost of revenue(1)(0)(1)(0) (8) 
Cost of goods and services sold(1)(0)     
Gross profit:584442029(0)7
Operating expenses(127)(117)(83)(90)(81)(91)(97)
Operating loss:(69)(73)(80)(70)(52)(91)(89)
Nonoperating income
(Investment Income, Nonoperating)
4310000
Interest and debt expense(0)      
Loss before gain (loss) on sale of properties:(66)(70)(78)(69)(52)(91)(89)
Other undisclosed net income (loss)(1)(1)0    
Net loss attributable to parent:(67)(70)(78)(69)(52)(91)(89)
Other undisclosed net income available to common stockholders, basic   000 
Net loss available to common stockholders, diluted:(67)(70)(78)(69)(51)(91)(89)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(67)(70)(78)(69)(52)(91)(89)
Comprehensive loss:(67)(70)(78)(69)(52)(91)(89)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)000(0)
Comprehensive loss, net of tax, attributable to parent:(67)(70)(78)(69)(52)(91)(89)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: